Medronic Acid

Medronic Acid

SCHEMBL556782

O=P([O-])([O-])CP(=O)([O-])[O-].[Tc+4]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SLC34A1 Q06495 1/20 0.33
KDM4E B2RXH2 1/20 0.31
MMP2 P08253 1/20 0.31
THRB P10828 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
BTN3A1 O00481 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Medronic Acid SCHEMBL29391188 0.96 SLC34A1 (0.31) SLC34A1
Medronic Acid SCHEMBL29390548 0.96 SLC34A1 (0.31) SLC34A1
Medronic Acid SCHEMBL409013 0.91 LMNA (0.35) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL2801380 0.91 SLC34A1 (0.33) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL5423104 0.91 SLC34A1 (0.33) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL9645616 0.91 SLC34A1 (0.33) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL5267588 0.91 SLC34A1 (0.43) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL8712848 0.91 SLC34A1 (0.33) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL8712850 0.91 SLC34A1 (0.33) SLC34A1KDM4EMMP2THRBMAPK1
Medronic Acid SCHEMBL15129297 0.91 SLC34A1 (0.33) SLC34A1KDM4EMMP2THRBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117683034-A Pyrrolo [1,2-B ] pyridazine derivatives 吉利德科学公司 2024-03-12 CN disclosed
CN-112513044-B Pyrrolo [1,2-B ] pyridazine derivatives 吉利德科学公司 2023-11-07 CN disclosed
US-20210205172-A1 DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT REGIMEN KIT INC (JP) 2021-07-08 US disclosed
EP-3838246-A1 DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT Regimen Kit, Inc. (JP) 2021-06-23 EP disclosed
WO-2020036231-A1 DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT レジメンキット株式会社 2020-02-20 WO disclosed
US-8674172-B2 Prostate cancer cell lines and their use in screening method INSTITUT GUSTAVE ROUSSY (FR) 2014-03-18 US disclosed
US-20120036587-A1 PROSTATE CANCER CELL LINES AND THEIR USE IN SCREENING METHOD INSTITUT GUSTAVE ROUSSY (FR) 2012-02-09 US disclosed
US-20100215137-A1 Method and apparatus for producing radioisotope JAPAN ATOMIC ENERGY AGENCY (JP) 2010-08-26 US disclosed
CN-1802090-A Boroproline compound combination therapy POINT THERAPEUTICS INC (US) 2006-07-12 CN disclosed
CN-1180841-C Method to enhance healing of sternum after sternotomy ������ҩ��ʽ���� 2004-12-22 CN disclosed
CN-1382058-A Method for promoting sternum healing after sternotomy KAKEN PHARMA CO LTD (JP) 2002-11-27 CN disclosed